eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2022
vol. 73
 
Share:
Send email
Share:
abstract:
Original paper

Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients

Dina Sweed
1
,
Aya Abd-Elbary
1
,
Eman Sweed
2
,
Asmaa Mosbeh
1
,
Inas Moaz
3
,
Taha Yassein
4
,
Shereen Elmashad
1

  1. Pathology Department, National Liver Institute, Menoufia University, Menoufia, Egypt
  2. Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Menofia, Egypt
  3. Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menofia, Egypt
  4. Hepato-pancreaticobiliary Surgery, National Liver Institute, Menoufia University, Menofia, Egypt
Pol J Pathol 2022; 73 (2): 88-98
DOI: https://doi.org/10.5114/pjp.2022.118700
Online publish date: 2022/08/10
View full text Get citation
 
PlumX metrics:
The pathogenesis of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) differs according to whether prior treatment with interferon (IFN) vs. direct-acting antiviral agents (DAAs) was administered. Cyclo- oxygenase-2 (COX-2), yes-associated protein 1 (YAP), and transcriptional co-activator with PDZ-binding motif (TAZ) play a crucial role in hepatocarcinogenesis. However, their roles in untreated or treated HCV-related HCC development have not been clarified.

Therefore, we performed an immunohistochemical study and stained tissue from 83 HCV-related HCC cases using antibodies against COX-2, YAP, and TAZ and correlated their expression with the clinicopathological characteri stics and survival data.

The cases were subdivided into 3 groups based on prior HCV treatment. In the 3 groups, COX-2 was significantly higher in HCC tissue compared with adjacent non-tumour liver tissue. However, the expression of YAP/TAZ was not significantly different between HCC and adjacent non-tumour tissue. We further grouped HCC cases into YAP+/TAZ+ and YAP–/TAZ– cases.

In the YAP+/TAZ+ cases, COX-2 was significantly associated with tumour size, tumour multifocality, and late pathologic stage. No significant difference was observed in COX-2 and TAZ expression as a result of IFN or DAA treatment; however, YAP was significantly higher in IFN-treated HCC. Cyclo-oxygenase-2 overexpression may play a role in late HCC development, while YAP/TAZ could play an early role in HCC progression. Sustained expression of combined YAP/TAZ could mediate the poor prognostic role of COX-2.
keywords:

COX-2, HCV, hepatocellular carcinoma, TAZ, YAP
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.